Prostate cancer is very common in elderly men in developed countries.
Unravelling of the molecular and biological processes that contribute to tumor development and progressive growth, including its heterogeneity, is a challenging task. The fusion of the genes ERG and TMPRSS2 is the most frequent genomic alteration in prostate cancer. ERG is an oncogene that encodes a member of the family of ETS transcription factors. At lower frequency other members of this gene family are also rearranged and overexpressed in prostate cancer. TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate. Most of the less frequent ETS fusion partners are also androgen-regulated and prostate-specific. During the last few years novel concepts of the process of gene fusion have emerged and initial experimental results explaining the function of the ETS genes ERG and ETV1 in prostate cancer have been published. In this review we focus on the most relevant ETS gene fusions and summarize the current knowledge of the role of ETS transcription factors in prostate cancer. Finally, we discuss the clinical relevance of TMRPSS2-ERG and other ETS gene fusions in prostate cancer.
Written by:
Gasi Tandefelt D, Boormans J, Hermans K, Trapman J. Are you the author?
Pathology, Erasmus Medical Centre, Rotterdam, Netherlands.
Reference: Endocr Relat Cancer. 2014 Mar 21. Epub ahead of print.
doi: 10.1530/ERC-13-0390
PubMed Abstract
PMID: 24659477
